The last day of PTAB Masters™ 2022 featured sessions on dealing with parallel litigation at the International Trade Commission (ITC) and district courts in Patent Trial and Appeal Board (PTAB) proceedings; life sciences and inter partes review (IPR); and the future of the PTAB. On the latter topic, speakers contemplated what lies in wait for the U.S. Patent and Trademark Office (USPTO) Director nominee, Kathi Vidal, who is likely to be confirmed, as well as how certain the Restoring America Invents Act is to be passed, and what changes it may include.
Recent Posts
- Harrity & Harrity Seeks FT Patent Attorney / Agent in Electrical or Mechanical Technologies
- Understanding IP Matters: Celebrated MIT Engineer and Entrepreneur Develops Medical Devices to Treat Cancer and Other Diseases
- CAFC Finds IPR Petitioner Did Not Rely on AAPA as Basis for Obviousness Grounds in Affirming PTAB Invalidation
- Foreign Price Controls: A Risk to U.S. Medical Innovation and Patient Access
- Other Barks & Bites for Friday, July 11: EGC Affirms Annulment of Rubik’s Cube Marks; Sysco Trade Secret Case Dismissal Affirmed by Fourth Circuit; and EU Advocate General Finds Member States Can Impose Measures to Protect News Content on Meta Platforms